Currently, a first-in-class RAD51 inhibitor, CYT-0851, is undergoing a Phase I/II clinical trial (NCT03997968), recruiting patients with refractory B-cell malignancies and solid tumors, including breast cancer (Table 3). Here, RAD51 is linked to breast cancer.